On November 17, Moderna, Inc. fell 3.19% in Regular Trading, trading around $209.315 per share, with turnover of $173 million.
The key catalyst was Morgan Stanley’s decision to raise its price target to $200 from $95 while maintaining an Equal Weight rating, a move that still left the stock above the revised target and reinforced a cautious market stance on near-term upside.
Background updates from the company’s recent analyst day showed expected year-end total liquidity of about $9 billion, projected 2027 cash costs of about $4 billion, an extension of its $1.5 billion credit facility to 2031, and a higher revenue growth outlook of 15% to 25%. Even so, recent trading suggests investors remain focused on oncology investment intensity, cost discipline, and execution pacing, limiting enthusiasm despite improved financial planning and prior better-than-expected quarterly results.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments